(NASDAQ: KURA) Kura Oncology's forecast annual revenue growth rate of 60.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Kura Oncology's revenue in 2026 is $104,029,000.On average, 17 Wall Street analysts forecast KURA's revenue for 2026 to be $14,932,206,089, with the lowest KURA revenue forecast at $5,261,601,243, and the highest KURA revenue forecast at $29,393,647,405. On average, 15 Wall Street analysts forecast KURA's revenue for 2027 to be $16,917,075,674, with the lowest KURA revenue forecast at $4,530,741,110, and the highest KURA revenue forecast at $47,968,406,798.
In 2028, KURA is forecast to generate $42,468,029,485 in revenue, with the lowest revenue forecast at $7,734,639,105 and the highest revenue forecast at $183,868,015,534.